Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate

IF 3.1 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2024-08-22 DOI:10.1111/jdi.14290

Andrzej S. Januszewski, Hayden K. Young, Kwok-Leung Ong, Liping Li, Rachel L. O’Connell, Timothy J. Lyons, Clare Kelly, Dessi P. Zaharieva, David R. Sullivan, Russell S. Scott, Anthony C. Keech, Alicia J. Jenkins, the FIELD Study Investigators

{"title":"Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate","authors":"Andrzej S. Januszewski, Hayden K. Young, Kwok-Leung Ong, Liping Li, Rachel L. O’Connell, Timothy J. Lyons, Clare Kelly, Dessi P. Zaharieva, David R. Sullivan, Russell S. Scott, Anthony C. Keech, Alicia J. Jenkins, the FIELD Study Investigators","doi":"10.1111/jdi.14290","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims/Hypothesis</h3>\n \n <p>In diabetes haptoglobin (Hp) 2 vs Hp 1 allelic product is associated with cardiac and renal complications. Few studies report both Hp phenotype and Hp levels. In a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial substudy we evaluated the Hp phenotype, Hp levels, and fenofibrate effects.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>In 480 adults with type 2 diabetes (T2D) the Hp phenotype was assessed and the Hp level quantified (both using ELISAs assays) in plasma from baseline, after 6 weeks of fenofibrate, and (in <i>n</i> = 200) at 2 years post-randomization to fenofibrate or placebo.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The Hp phenotypes 1-1, 2-1, and 2-2 frequencies were 15%, 49%, and 36%, respectively. Baseline Hp levels differed by phenotype (<i>P</i> < 0.0001) and decreased (median 21%) after 6 weeks fenofibrate in all phenotypes (adjusted mean (95% CI): −0.27 (−0.32, −0.23) mg/mL in Hp 1-1, −0.29 (−0.31, −0.27) mg/mL in Hp 2-1 and −0.05 (−0.07, −0.02) mg/mL in Hp 2-2 (<i>P</i> = 0.005 and <i>P</i> = 0.055 vs Hp 1-1 and Hp 2-1, respectively)). At 2 years post-randomization the Hp levels in the placebo group had returned to baseline, whilst the fenofibrate-group levels remained similar to the 6 week levels.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In type 2 diabetes, Hp levels differ by Hp phenotype and are decreased by fenofibrate in all phenotypes, but the effect is diminished in Hp 2-2.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 11","pages":"1663-1668"},"PeriodicalIF":3.1000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14290","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14290","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims/Hypothesis

In diabetes haptoglobin (Hp) 2 vs Hp 1 allelic product is associated with cardiac and renal complications. Few studies report both Hp phenotype and Hp levels. In a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial substudy we evaluated the Hp phenotype, Hp levels, and fenofibrate effects.

Materials and Methods

In 480 adults with type 2 diabetes (T2D) the Hp phenotype was assessed and the Hp level quantified (both using ELISAs assays) in plasma from baseline, after 6 weeks of fenofibrate, and (in n = 200) at 2 years post-randomization to fenofibrate or placebo.

Results

The Hp phenotypes 1-1, 2-1, and 2-2 frequencies were 15%, 49%, and 36%, respectively. Baseline Hp levels differed by phenotype (P < 0.0001) and decreased (median 21%) after 6 weeks fenofibrate in all phenotypes (adjusted mean (95% CI): −0.27 (−0.32, −0.23) mg/mL in Hp 1-1, −0.29 (−0.31, −0.27) mg/mL in Hp 2-1 and −0.05 (−0.07, −0.02) mg/mL in Hp 2-2 (P = 0.005 and P = 0.055 vs Hp 1-1 and Hp 2-1, respectively)). At 2 years post-randomization the Hp levels in the placebo group had returned to baseline, whilst the fenofibrate-group levels remained similar to the 6 week levels.

Conclusions

In type 2 diabetes, Hp levels differ by Hp phenotype and are decreased by fenofibrate in all phenotypes, but the effect is diminished in Hp 2-2.

Abstract Image

查看原文本刊更多论文

2 型糖尿病患者的aptoglobin表型和水平以及非诺贝特的影响。

目的/假设：糖尿病患者血红蛋白（Hp）2 与 Hp 1 的等位基因产物与心脏和肾脏并发症有关。很少有研究同时报告 Hp 表型和 Hp 水平。在一项非诺贝特干预和降低糖尿病事件（FIELD）试验的子研究中，我们评估了Hp表型、Hp水平和非诺贝特的效果：在480名2型糖尿病（T2D）成人患者中，评估了血浆中的Hp表型并量化了血浆中的Hp水平（均采用ELISAs检测法），包括基线、服用非诺贝特6周后以及（n = 200）随机服用非诺贝特或安慰剂2年后的血浆中的Hp水平：Hp表型1-1、2-1和2-2的频率分别为15%、49%和36%。不同表型的 Hp 基线水平不同（P 结论：Hp 表型 1-1、2-1 和 2-2 的频率分别为 15%、49% 和 36%：在 2 型糖尿病患者中，Hp 水平因 Hp 表型而异，非诺贝特可降低所有表型患者的 Hp 水平，但对 Hp 2-2 型患者的影响较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).